Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, multicenter dose-escalation study to determine the RP2D of CI
8993 for administration to patients with relapsed/refractory solid tumors by evaluating the
safety and tolerability and characterizing the PK, PD, and anti cancer activity of CI-8993 in
this population.